Agenus (AGEN) Scheduled to Post Earnings on Tuesday

Agenus (NASDAQ:AGEN - Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($3.10) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The company had revenue of $83.80 million for the quarter, compared to analyst estimates of $54.21 million. On average, analysts expect Agenus to post $-8 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Agenus Trading Down 5.0 %

AGEN stock traded down $0.64 during mid-day trading on Tuesday, hitting $12.12. 1,182,614 shares of the company were exchanged, compared to its average volume of 694,855. Agenus has a 1-year low of $4.78 and a 1-year high of $42.60. The stock has a market capitalization of $253.91 million, a PE ratio of -0.85 and a beta of 1.26. The business has a 50 day simple moving average of $10.93 and a 200-day simple moving average of $13.57.

Insider Activity at Agenus

In other news, insider Garo H. Armen acquired 25,000 shares of Agenus stock in a transaction that occurred on Thursday, February 15th. The shares were acquired at an average price of $13.00 per share, for a total transaction of $325,000.00. Following the transaction, the insider now directly owns 31,298 shares of the company's stock, valued at approximately $406,874. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AGEN shares. B. Riley reduced their price target on Agenus from $120.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, March 18th. StockNews.com assumed coverage on Agenus in a report on Wednesday, April 17th. They issued a "hold" rating on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $160.00 price target on shares of Agenus in a research note on Thursday, March 14th.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.